CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

Начало・Списък с акции・Ocugen Inc
Search

Ocugen Inc

Затворен

1.18 -4.07

Силна покупка

Обновена цена 10.06.2026 г., 19:59 ч. UTC

КупиПродай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.18

Максимум

1.24

Ключови измерители

By Trading Economics

Приходи

-1.5M

-19M

Продажби

1.7M

1.5M

EPS

-0.06

Марж на печалбата

-1,250.946

Служители

116

EBITDA

-987K

-17M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+821.77% upside

Дивиденти

By Dow Jones

Следващи печалби

31.07.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-193M

433M

Предишно отваряне

5.25

Предишно затваряне

1.18

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.06.2026 г., 23:36 ч. UTC

Печалби

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Прочетени

10.06.2026 г., 23:19 ч. UTC

Горещи акции

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Прочетени

10.06.2026 г., 23:09 ч. UTC

Значими двигатели на пазара

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Прочетени

10.06.2026 г., 23:04 ч. UTC

Печалби

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Прочетени

10.06.2026 г., 20:44 ч. UTC

Значими двигатели на пазара

Caterpillar Raises Quarterly Dividend 8%

DJ

Прочетени

10.06.2026 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Northern Star Should Take No Options Off The Table

DJ

Прочетени

10.06.2026 г., 23:48 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Прочетени

10.06.2026 г., 23:48 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Прочетени

10.06.2026 г., 23:47 ч. UTC

Пазарно говорене

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Прочетени

10.06.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Прочетени

10.06.2026 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Прочетени

10.06.2026 г., 23:38 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

DJ

Прочетени

10.06.2026 г., 23:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

DJ

Прочетени

10.06.2026 г., 23:38 ч. UTC

Пазарно говорене

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Прочетени

10.06.2026 г., 23:32 ч. UTC

Пазарно говорене

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Прочетени

10.06.2026 г., 23:20 ч. UTC

Пазарно говорене

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Прочетени

10.06.2026 г., 22:05 ч. UTC

Пазарно говорене

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Прочетени

10.06.2026 г., 21:57 ч. UTC

Печалби

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Прочетени

10.06.2026 г., 21:52 ч. UTC

Печалби

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Прочетени

10.06.2026 г., 21:35 ч. UTC

Печалби

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Прочетени

10.06.2026 г., 21:22 ч. UTC

Печалби

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Прочетени

10.06.2026 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

DJ

Прочетени

10.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

DJ

Прочетени

10.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

DJ

Прочетени

10.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

DJ

Прочетени

10.06.2026 г., 20:39 ч. UTC

Пазарно говорене
Печалби

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Прочетени

10.06.2026 г., 20:34 ч. UTC

Печалби

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Прочетени

10.06.2026 г., 20:33 ч. UTC

Печалби

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Прочетени

10.06.2026 г., 20:33 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

DJ

Прочетени

10.06.2026 г., 20:33 ч. UTC

Пазарно говорене
Печалби

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Прочетени

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

821.77% нагоре

12-месечна прогноза

Среден 11.43 USD  821.77%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

7

Купи

0

Задържане

0

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Други акции от сектора

CAT

Caterpillar Inc.

857.12

↓-6.25%

GE

General Electric Co.

319.5

↓-3.32%

GEV.US

GE Vernova LLC

866.14

↓-5.57%

RTX

Raytheon Technologies Corp.

177.9

↓-1.87%

BA

Boeing Co.

209.07

↓-2.53%
help-icon Live chat